Reuters: Regulatory News: FDA grants priority review status to Gilead's hepatitis C drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA grants priority review status to Gilead's hepatitis C drug Jun 7th 2013, 22:08 June 7 | Fri Jun 7, 2013 6:08pm EDT June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir. The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies. The FDA set a review date of Dec. 8 for the drug, Gilead said. Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue. Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions